Диссертация (1173295), страница 16
Текст из файла (страница 16)
Paraneoplastic syndromes. / R.B. Darnell, J.B. Posner. - New York:Oxford University Press, 2011.-482 p.74. Dau, P.C. Plasmapheresis and immunosuppressive drug therapy in myastheniagravis. / P.C. Dau, J.M. Lindstrom, C.K. Cassel, E.H. Denys, E.E. Shev, L.E. Spitler.
//The New England Journal of Medicine. – 1977. - №297. P. 1134-1140.75.Dempfle, C.E. The use of soluble fibrin in evaluating the acute and chronichypercoagulable state. / C.E. Dempfle. // Thrombosis and Haemostasis. – 1999. №82(2). – P. 673-683.76. Duby, J.J. Diabetic neuropathy: an intensive review. / J.J. Duby, R.K. Campbell,S.M. Setter, J.R. White, K.A. Rasmussen. // The American Journal of Health-SystemPharmacy.
– 2004. - № 61. – P. 160–173.77. Edwards, J.L. Diabetic neuropathy: mechanisms to management. / J.L. Edwards,A.M. Vincent, H.T. Cheng, E.L. Feldman. // Pharmacology and Therapeutics. – 2008. № 120. - P. 1– 34.78. Fardet, L. Factors associated with underlying malignancy in a retrospective cohortof 121 patients with dermatomyositis.
/ L. Fardet, A. Dupuy, M. Gain, A. Kettaneh, P.Chérin, H. Bachelez, L. Dubertret, C. Lebbe, P. Morel, M. Rybojad. // Medicine(Baltimore). – 2009. - № 88(2). – P. 91-97.79. Ferroni, P. Plasma plasminogen activator inhibitor-1 (PAI-1) levels in breast cancer- relationship with clinical outcome. / P.
Ferroni, M. Roselli, I. Portarena, V. Formica,S. Riondino, L. Costarelli, A. Melino, G. Massimiani, F. Cavaliere, R. Palmirotta, F.Guadagni. // Anticancer Research. – 2014. - № 34. – P. 1153-1161.80. Forsyth, P.A. Motor neuron syndromes in cancer patients. / P.A. Forsyth, J.Dalmau, F. Graus, V.
Cwik, M.K. Rosenblum, J.B. Posner. // Annals of Neurology. –1997. - № 41(6). – P. 722-730.9881. Fukumoto, K. Preoperative plasma D-dimer level is an independent prognosticfactor in patients with completely resected non-small cell lung cancer. / K. Fukumoto,T. Taniguchi, N. Usami, K. Kawaguchi, T. Fukui, F. Ishiguro, S.
Nakamura, K. Yokoi.// Surgery Today. – 2015. - № 45. – P.63-67.82. Galanis, E. Neuronal autoantibody titers in the course of small-cell lung carcinomaand platinum-associated neuropathy. / E. Galanis, S. Frytak, K.M. Jr Rowland, J.A.Sloan, V.A. Lennon. // Cancer Immunology, Immunotherapy. – 1999. - № 48(2-3). – P.85-90.83. Gatti, G. Paraneoplastic neurological disorders in breast cancer. / G. Gatti, S.Simsek, A.
Kurne, et al. // Breast. – 2003. - № 12(3). – P. 203-207.84. Graus, F. Anti-Hu antibodies in patients with small-cell lung cancer: associationwith complete response to therapy and improved survival. / Graus F., Dalmou J., ReñéR. et al. // Journal of Clinical Oncology. – 1997. - № 15(8).
– P. 2866-2872.85. Graus, F. Recommended diagnostic criteria for paraneoplastic neurologicalsyndromes. / F. Graus, J.Y. Delattre, J.C. Antoine, J. Dalmau, B. Giometto, W. Grisold,J. Honnorat, P.S. Smitt, C.H. Vedeler, J.J. Verschuuren, A. Vincent, R.
Voltz. // Journalof Neurology, Neurosurgery and Psychiatry. - 2004. - № 75(8). – P. 1135-1140.86. Graus, F. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200patients. / F. Graus, F. Keime-Guibert, R. Reñe, B. Benyahia, T. Ribalta, C. Ascaso, G.Escaramis, J.Y. Delattre. // Brain. – 2001.
- №124(6). – P. 1138-1148.87. Graus F. Anti-glial nuclear antibody: marker of lung cancer-related paraneoplasticneurological syndromes. / F. Graus, A. Vincent, P. Pozo-Rosich, L. Sabater, A. Saiz, B.Lang, J. Dalmau. // Journal of Neuroimmunology. – 2005. – № 165(1-2). – P. 166-171.88. Grisold, W. Anti-tumour therapy in paraneoplastic neurological disease.
/ W.Grisold, M. Drlicek, U. Liszka-Setinek, E. Wondrusch // Clinical of Neurology andNeurosurgery. – 1995. - № 97(1). – P. 106-111.89. Hauspy, J. Paraneoplastic syndrome in vaginal melanoma: a case report and reviewof the literature. / J. Hauspy, A. Nevin, I. Harley, W. Mason, I. Quirt, D. Ghazarian, S.Laframboise // International Journal of Gynecological Cancer. - 2007. - № 17(5). –P.1159-1163.9990.
Herbst, R.S. Lung cancer. / R.S. Herbst, J.V. Heymach, S.M. Lippman. // NewEngland Journal of Medicine. – 2008. - № 359(13). P. 1367-1380.91. Hill, C.L. Frequency of specific cancer types in dermatomyositis and polymyositis:a population-based study. / C.L. Hill, Y.
Zhang, B. Sigurgeirsson, E. Pukkala, L.Mellemkjaer, A. Airio, S.R. Evans, D.T. Felson. // The Lancet. – 2001. - № 357 (9250).– P. 96-100.92. Hudson, C.N. Paraneoplastic syndromes in patients with ovarian neoplasia. / C.N.Hudson, M. Curling, P. Potsides, D.G. Lowe // Journal of the Royal Society ofMedicine. - 1994. - № 87(6). – P. 368-369.93. Jarius, S. Relative frequency of VGKC and ‘classical’ paraneoplastic antibodies inpatients with limbic encephalitis. / S. Jarius, L.A. Hoffmann, O. Stich, et al. // Journal ofneurology. - 2008.
- № 255. – P. 1100-1101.94. Johnson, V. Immune mediated neurologic dysfunction as a paraneoplastic syndromein renal cell carcinoma. / V. Johnson, N. Friedman, N.A. Haller, C. Hagel. // Journal ofNeurooncology. – 2008. - № 90(3). – P. 279-281.95. Park, K.J. Evaluation of the Diagnostic Performance of Fibrin Monomer inDisseminated Intravascular Coagulation. / K.J. Park, E.H. Kwon, H.J. Kim, S.H. Kim. //Korean Journal Laboratory Medicine. - 2011. - № 31. – P. 143-147.96.
Keime-Guibert, F. Treatment of paraneoplastic neurological syndromes withantineuronal antibodies (Anti-Hu, anti-Yo) with a combination of immunoglobulins,cyclophosphamide, and methylprednisolone. / F. Keime-Guibert, F. Graus, A.Fleury, R. René, J. Honnorat, P. Broet, J.Y. Delattre. // Journal of Neurology,Neurosurgery and Psychiatry. - 2000. - № 68(4). – P. 479-482.97. Kessel, A. Intravenous immunoglobulin therapy affects T regulatory cells byincreasing their suppressive function. / A.
Kessel, H. Ammuri, R. Peri, et al. // Journalof immunology. - 2007. - № 179. – P. 5571-5575.98. Koga, S. A novel molecular marker for thrombus formation and life prognosis-clinical usefulness of measurement of soluble fibrin monomer-fibrinogen complex (SF)./ S. Koga // Rinsho Byori. – 2004. - № 52(4). – P. 355-361.99. Komurcuoglu, B. Prognostic value of plasma D-dimer levels in lung carcinoma. / B.Komurcuoglu, S. Ulusoy, M. Gayaf, A. Guler, E.
Ozden. // Tumori. – 2011. - №97. – P.743-748.100100. Kuntzer, T. Clinical features and pathophysiological basis of sensoryneuronopathies (ganglionopathies). / T. Kuntzer, J.C. Antoine, J. A. Steck. // Muscleand Nerve. – 2004. - № 30(3). – P. 255–268.101. Linkins, L.A. Review of D- dimer testing: Good, Bad, and Ugly. / L.A. Linkins, S.Takach Lapner. // International Journal of Laboratory Hematology. - 2017. - № 39(1). –P. 98–103.102.
Lambert, E.H. Defect of neuromuscular conduction associated with malignantneoplasms. / E.H. Lambert, L.M. Eaton, E.D. Rooke. //American Journal of Physiology.- 1956. – № 187. - P. 612– 613.103. Leko, M. Soluble fibrin monomer degradation products as a potential usefulmarker for hypercoagulable states with accelerated fibrinolysis. / M.
Leko. // ClinicaChimica Acta. - 2007. - № 386. – P. 38.104. Lucchinetti, C.F. Paraneoplastic and oncologic profiles of patients seropositive fortype 1 antineuronal nuclear autoantibodies. / C.F. Lucchinetti, D.W. Kimmel, V.A.Lennon. // Journal of Neurology. – 1998. - № 50(3). – P. 652-657.105.
Martín Escudero, J.C. Necrotizing myelopathy associated with neoplasia. Aclinico-pathological study of 2 cases and a review of the literature. / J.C. MartínEscudero, M. Aparicio Blanco, H. Borrego Pintado, A. Villar Negro, J.L. CarreteroSastre, C. Velasco Fernández. // Anales de Medicina Interna. – 1991. - № 8(10).
– P.497-500.106. Mastaglia, F.L. Inflammatory myopathies: clinical, diagnostic and therapeuticaspects. / Mastaglia F.L., Garlepp M.J., Phillips B.A., Zilko P.J. // Muscle and Nerve. –2003. -№ 27(4). – P. 407-425.107. Dyck, P.I. Peripheral neuropathy. Carcinomatous neuropathy. / P.I. Dyck, P.K.Thomas, E. Lambert, R. Bunge. // Muscle and Nerve. – 1984. - № 7(8). – P.
2180-2190.108. Nakashima, J. Tumor necrosis factor and coagulopathy in patients with prostatecancer. / J. Nakashima, M. Tachibana, M. Ueno, S. Baba, H. Tazaki. // CancerResearch. - 1995. -№ 55. – P. 4881-4885.109. Oh, S.J. Electrophysiological diagnostic criteria of Lambert-Eaton myasthenicsyndrome. / S.J. Oh, K. Kurokawa, G.C.
Jr. Claussen. // Muscle and Nerve. – 2005. - №32(4). – P. 515-20.101110. Okajima, K. Direct evidence for systemic fibrinogenolysis in a patient withmetastatic prostatic cancer. / K. Okajima, I. Kohno, J. Tsuruta, H. Okabe, K. Takatsuki,B.R. Binder. // Thrombosis Research. - 1992. - № 66. – P. 717-727.111. Palma, J.A.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
